GLP1 Europe › About

About this site

Last updated 14 August 2026

Why this exists

Search for almost any question about retatrutide, tirzepatide or semaglutide and you will get three kinds of result. Medical publishers writing for an American audience, who get European regulation wrong or ignore it. Sellers, whose pages are built to end in a purchase. And forums, where confident answers and wrong answers look identical.

What is missing is a plain, dated, European-specific reference that treats the reader as capable of handling an accurate answer, including when the accurate answer is inconvenient. That is what this site tries to be.

The European part matters more than it sounds. The United Kingdom now licenses medicines separately from the European Union and the two have visibly diverged. Reimbursement is decided country by country and changes several times a year. A page written for a reader in Ohio is not merely less useful in Tallinn or Lyon, it is often actively wrong.

Ownership and funding

GLP1 Europe is published by the same company that operates RetaNord, a European research peptide supplier.

We are stating that plainly because you should be able to weigh it. Here is what we do about it:

• Nothing is sold here. No products, no prices, no basket, no affiliate links, no discount codes.
• No page on this site links to RetaNord, and there is no tracking that connects a reader here to a visit there. A RetaNord panel appears at the foot of these pages, and on the country briefings we email. It is an image, not a link, and nothing passes between the two sites. We are telling you plainly rather than hiding it.
• No advertising on the site, from us or anyone else. No third party has ever bought space here and none can.
• No sponsored content. No pharmaceutical company, supplier or clinic has paid for, reviewed, or been given sight of anything published here.
• The site costs a few euros a month to run and is funded by its publisher. There is no revenue model attached to it.
• The emails are editorial, and they carry our own panel. You can ask for a country briefing, and be told when something changes: a filing, an approval, a new national rule. The briefing ends with a RetaNord panel, because the same company publishes both. Nothing from any third party appears in them, ever. Your address is not sold or shared, and one click unsubscribes.

You are entitled to read the pages more sceptically because of who publishes them. We would rather you do that with the facts in front of you than discover the connection later. Where our own commercial interest points one way and the evidence points the other, we have followed the evidence. The page on what "research use only" means in law is the clearest example, and it is not a comfortable page for a peptide supplier to publish.

Editorial policy

What we publish

• Regulatory status, sourced to the regulator that decided it, with the date it was checked
• Clinical trial results, sourced to the published paper or the company's own release, with participant numbers and trial length so the figure can be judged
• Legal provisions, cited by article number so you can read them yourself
• Explanations of mechanism, written for someone with no biology background

What we refuse to publish

• Dosing, titration schedules, or instructions for use. Not for approved medicines and certainly not for unapproved ones. Those belong with a prescriber who knows your history.
• Reconstitution or injection guidance. Same reason.
• Predicted approval dates presented as fact. Where a company has announced a filing intention we say so and attribute it. Everything else is speculation, and it is usually speculation published by someone who benefits from you not waiting.
• Sourcing advice. We will explain what a regulatory system provides and what buying outside it does not. We will not tell anyone where to buy anything.
• Before-and-after imagery or personal testimonials. They persuade without informing.

How sources are chosen

In descending order of preference: the regulator that made the decision, the trial registry entry, the peer-reviewed publication, the company's own regulatory announcement, then reputable specialist journalism. Where a primary source could not be reached directly and a secondary one was used, we say so on the page.

Peptide vendor sites are never used as sources, including for factual questions where they rank highly. On several of the legal questions covered here, vendor content was close to the only thing available in search results. That absence of independent analysis is itself worth knowing, and we have said so on the relevant page rather than filling the gap with someone's marketing copy.

Dates and accuracy

Every page carries a "last checked" date. This is deliberate and it is not decoration. Regulatory status and reimbursement rules in this field change monthly. A page without a date is asking you to trust that it is current, and most are not.

Where sources conflict, we say so rather than picking the more flattering number. Where two figures are both correct because they answer different questions, as with the efficacy and treatment-regimen estimands reported by every trial in this class, we explain the difference instead of quoting whichever is larger.

Where we could not verify something, it is left out. There are several deliberate blanks in the country tables for exactly this reason.

What this site is not

Corrections and contact

If something here is wrong, we want to know, and a citation makes it much faster to fix.

Email hello@glp1europe.com. Useful corrections include the page, the specific claim, and a source. Material corrections are made on the page and the "last checked" date is updated.

We do not accept guest posts, link exchanges, sponsored placements, or requests to add commercial links. Please do not ask.

GLP1 Europe publishes background information about GLP-1 receptor agonists and related molecules. It does not sell, supply, advertise or recommend any medicine, and it does not provide medical advice, diagnosis or treatment.